How Can Restricting Compounded Peptides Affect Current Gray Market Users?

Nate Hill, co-founder & CEO of Strive Pharmacy, addresses concerns about where patients would turn if the FDA moves to restrict compounded peptides sourced through gray-market channels. Hill points out that many of these research-grade peptide sellers include disclaimers on their websites stating the products are intended for research use only, not human use, a distinction he calls a clear red flag, since it is widely understood that these compounds are actually being purchased for individual human use.

Central to Hill's argument is the contrast between the unregulated gray market and the compounding pharmacy industry, which operates under oversight from state boards of pharmacy that in turn follow FDA guidelines. He details the protocols compounding pharmacies must already meet: sourcing active pharmaceutical ingredients from vetted, FDA-regulated and inspected suppliers that follow current Good Manufacturing Practice (GMP) standards, adhering to required testing, and complying with limits on batch sizes. These are safeguards, he notes, that gray-market research chemical companies are not required to follow.

Hill raises specific concerns about the range of sourcing channels used by research-grade sellers, arguing that even when some products may be of reasonable quality, there is no mechanism to verify or enforce that quality consistently across the market. He questions marketing claims made by these companies, asking who would be responsible for catching it if a company were misrepresenting its product to consumers, given the absence of a regulatory body overseeing this segment.

Taken together, Hill's response suggests that restricting access through legitimate compounding channels, without addressing the demand driving gray-market use, does little to resolve the underlying regulatory gap, and that the more durable solution lies in extending oversight already proven in compounding pharmacy to the peptide space itself.